Cargando…

Lymph node ratio predicts overall survival in patients with stage II non-small cell lung cancer: a population-based SEER analysis

BACKGROUND: In non-small-cell lung cancer (NSCLC), there are many factors that affect prognosis, and the lymph node ratio (LNR) may play a significant role. Our study aimed to confirm the value of the LNR in the prognosis of patients with stage II NSCLC. METHODS: Patient data were obtained from the...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Nan, Wu, Bo, Zhang, Xiang, Chen, Jianhui, Xiang, Zhongtian, Wei, Yiping, Zhang, Wenxiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388711/
https://www.ncbi.nlm.nih.gov/pubmed/35982330
http://dx.doi.org/10.1007/s12672-022-00542-w
_version_ 1784770270857265152
author Feng, Nan
Wu, Bo
Zhang, Xiang
Chen, Jianhui
Xiang, Zhongtian
Wei, Yiping
Zhang, Wenxiong
author_facet Feng, Nan
Wu, Bo
Zhang, Xiang
Chen, Jianhui
Xiang, Zhongtian
Wei, Yiping
Zhang, Wenxiong
author_sort Feng, Nan
collection PubMed
description BACKGROUND: In non-small-cell lung cancer (NSCLC), there are many factors that affect prognosis, and the lymph node ratio (LNR) may play a significant role. Our study aimed to confirm the value of the LNR in the prognosis of patients with stage II NSCLC. METHODS: Patient data were obtained from the Surveillance, Epidemiology and End Results (SEER) database. The classification for the LNR was best determined using the X-tile method. The correlation between the LNR and overall survival (OS) was validated after the Kaplan–Meier analysis was performed. To determine the correlation between the LNR and survival, stratification and the Cox regression analysis were used. RESULTS: In our study, 14,183 stage II NSCLC patients were included. Among them, 8303 patients had N1 disease. According to the X-tile analysis, the optimal critical points for the LNR in N1 patients with NSCLC was 0.21 and 0.38. We categorized the cohorts as low (LNR-L ≤ 0.21; n = 5158, 62.1%), medium (0.21 < LNR-M ≤ 0.38; n = 1736, 20.9%), and high (LNR-H > 0.38; n = 1409, 17.0%). According to the Kaplan–Meier analysis, the patients with a high LNR were considerably worse than those with a medium or low LNR (P < 0.001), which was also proven by stratified and multivariate analyses. The value of the LNR was reflected in all the subgroup analyses, especially in patients ages < 60 years. The multivariate competing risks regression analysis revealed that younger age, female sex, T1 disease, adenocarcinoma and N0 disease was associated with a better prognosis after controlling for potential confounders (P < 0.001). CONCLUSIONS: For patients with stage II NSCLC, the LNR is valuable for assessing prognosis. A higher LNR indicates a worse prognosis.
format Online
Article
Text
id pubmed-9388711
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-93887112022-08-20 Lymph node ratio predicts overall survival in patients with stage II non-small cell lung cancer: a population-based SEER analysis Feng, Nan Wu, Bo Zhang, Xiang Chen, Jianhui Xiang, Zhongtian Wei, Yiping Zhang, Wenxiong Discov Oncol Research BACKGROUND: In non-small-cell lung cancer (NSCLC), there are many factors that affect prognosis, and the lymph node ratio (LNR) may play a significant role. Our study aimed to confirm the value of the LNR in the prognosis of patients with stage II NSCLC. METHODS: Patient data were obtained from the Surveillance, Epidemiology and End Results (SEER) database. The classification for the LNR was best determined using the X-tile method. The correlation between the LNR and overall survival (OS) was validated after the Kaplan–Meier analysis was performed. To determine the correlation between the LNR and survival, stratification and the Cox regression analysis were used. RESULTS: In our study, 14,183 stage II NSCLC patients were included. Among them, 8303 patients had N1 disease. According to the X-tile analysis, the optimal critical points for the LNR in N1 patients with NSCLC was 0.21 and 0.38. We categorized the cohorts as low (LNR-L ≤ 0.21; n = 5158, 62.1%), medium (0.21 < LNR-M ≤ 0.38; n = 1736, 20.9%), and high (LNR-H > 0.38; n = 1409, 17.0%). According to the Kaplan–Meier analysis, the patients with a high LNR were considerably worse than those with a medium or low LNR (P < 0.001), which was also proven by stratified and multivariate analyses. The value of the LNR was reflected in all the subgroup analyses, especially in patients ages < 60 years. The multivariate competing risks regression analysis revealed that younger age, female sex, T1 disease, adenocarcinoma and N0 disease was associated with a better prognosis after controlling for potential confounders (P < 0.001). CONCLUSIONS: For patients with stage II NSCLC, the LNR is valuable for assessing prognosis. A higher LNR indicates a worse prognosis. Springer US 2022-08-18 /pmc/articles/PMC9388711/ /pubmed/35982330 http://dx.doi.org/10.1007/s12672-022-00542-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Feng, Nan
Wu, Bo
Zhang, Xiang
Chen, Jianhui
Xiang, Zhongtian
Wei, Yiping
Zhang, Wenxiong
Lymph node ratio predicts overall survival in patients with stage II non-small cell lung cancer: a population-based SEER analysis
title Lymph node ratio predicts overall survival in patients with stage II non-small cell lung cancer: a population-based SEER analysis
title_full Lymph node ratio predicts overall survival in patients with stage II non-small cell lung cancer: a population-based SEER analysis
title_fullStr Lymph node ratio predicts overall survival in patients with stage II non-small cell lung cancer: a population-based SEER analysis
title_full_unstemmed Lymph node ratio predicts overall survival in patients with stage II non-small cell lung cancer: a population-based SEER analysis
title_short Lymph node ratio predicts overall survival in patients with stage II non-small cell lung cancer: a population-based SEER analysis
title_sort lymph node ratio predicts overall survival in patients with stage ii non-small cell lung cancer: a population-based seer analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388711/
https://www.ncbi.nlm.nih.gov/pubmed/35982330
http://dx.doi.org/10.1007/s12672-022-00542-w
work_keys_str_mv AT fengnan lymphnoderatiopredictsoverallsurvivalinpatientswithstageiinonsmallcelllungcancerapopulationbasedseeranalysis
AT wubo lymphnoderatiopredictsoverallsurvivalinpatientswithstageiinonsmallcelllungcancerapopulationbasedseeranalysis
AT zhangxiang lymphnoderatiopredictsoverallsurvivalinpatientswithstageiinonsmallcelllungcancerapopulationbasedseeranalysis
AT chenjianhui lymphnoderatiopredictsoverallsurvivalinpatientswithstageiinonsmallcelllungcancerapopulationbasedseeranalysis
AT xiangzhongtian lymphnoderatiopredictsoverallsurvivalinpatientswithstageiinonsmallcelllungcancerapopulationbasedseeranalysis
AT weiyiping lymphnoderatiopredictsoverallsurvivalinpatientswithstageiinonsmallcelllungcancerapopulationbasedseeranalysis
AT zhangwenxiong lymphnoderatiopredictsoverallsurvivalinpatientswithstageiinonsmallcelllungcancerapopulationbasedseeranalysis